Dose 1 — Priming the Immune System
First HBV vaccine dose activates naive B cells.
- HBsAg: Antigen (yeast-expressed surface antigen)
- <1: Anti-HBs titer (mIU/mL, below detectable protection)
- 1 / 3: Doses given (0-1-6 month schedule)
- 2-4 wk: Response window (before antibodies appear)
Antigen presentation begins
Antigen-presenting cells capture and display HBsAg.
Naive B cells engage
Naive B cells recognize the surface antigen.
Single-dose protection stays under 30 percent.
Priming is not protection
One dose rarely reaches protective titer levels.
Dose 2 — Boosting the Response
Second dose expands memory B cell populations.
- 10-50: Anti-HBs titer (mIU/mL, many reach protection early)
- 2 / 3: Doses given (second scheduled injection)
- 4 wk: Minimum interval (since dose 1)
- ~75%: Seroconversion rate (after two doses)
Memory pool expansion
Memory B cells proliferate faster after the boost.
Affinity maturation
Antibody affinity improves with repeated exposure.
Skipping dose 3 risks fading protection later.
Steeper titer climb
Titers rise more steeply after the second dose.
Rising Anti-HBs Titer
Antibody levels climb steadily between vaccine doses.
- Exponential: Growth pattern (days 10-30 post-dose)
- Years: Anti-HBs half-life (long-lived circulating antibody)
- Decades: Memory B cells (immune memory outlasts titer)
- Wide: Response spread (age, weight, smoking affect rise)
Plasma cell secretion
Plasma cells secrete antibody continuously into blood.
Exponential rise
Titer growth follows a steep exponential curve.
Obesity and smoking blunt the antibody rise.
Slow responders
Poor responders rise more slowly toward protection.
Dose 3 — Completing the Series
Final dose locks in durable long-term immunity.
- 3 / 3: Doses given (series now complete)
- >100: Anti-HBs titer (mIU/mL typical after dose 3)
- Many yrs: Protection length (often lifelong in responders)
- ~5-10%: Non-responders (may need revaccination)
Strongest antibody surge
Third dose triggers the largest titer jump.
High-affinity memory
High-affinity memory cells dominate the response.
Delayed dose 3 still restores full protection.
Timing still matters
Completion timing affects lasting immunity strength.
Protective Titer Achieved
Anti-HBs above 10 mIU/mL confers lasting protection.
- 10: Protective threshold (mIU/mL, WHO-recognized cutoff)
- 100-1000+: Typical peak titer (mIU/mL in responders)
- 20+ yrs: Protection duration (immune memory persists)
- >95%: Vaccine efficacy (in healthy responders)
Memory outlasts titer
Immune memory persists even as titers fade.
Protection outlasts detectable antibody levels.
Breakthrough risk drops
Breakthrough infection risk drops sharply now.
Boosters rarely needed
Booster doses are rarely needed afterward.